Should You Stop a GLP-1 Before Surgery? 2026 Guidance
Updated 2026 guidance on GLP-1 medications, anesthesia, and pulmonary aspiration risk. What the ASA, MHRA, and FDA say, and why the stop-or-continue call is your provider's.
Should You Stop a GLP-1 Before Surgery? What the 2026 Guidance Says **Whether to stop or continue a GLP-1 medication before surgery or anesthesia is a decision your surgeon and anesthesiologist make with you, not a single fixed rule you apply on your own. The current direction has shifted. In October 2024, the American Society of Anesthesiologists (ASA) multi-society guidance, reaffirmed through 2025, replaced the earlier 2023 advice to simply hold the drug with a risk-stratified approach: most patients can continue their GLP-1 but should switch to clear liquids and fast from solids for 24 hours before a procedure. The reason for the caution is that GLP-1 medications slow gastric emptying, which can leave food in the stomach even after standard fasting and raise the risk of pulmonary aspiration under anesthesia. The FDA added a pulmonary-aspiration warning to GLP-1 drug labels, and the UK MHRA issued a 2025 drug safety alert covering both GLP-1 and dual GIP/GLP-1 receptor agonists. Always defer to the clinicians managing your specific procedure.** If you take a GLP-1 medication such as [semaglutide](/peptides/semaglutide) or [tirzepatide](/peptides/tirzepatide) and have a procedure scheduled, the question of what to do beforehand is a common and reasonable one. This article explains what changed, why the worry exists in the first place, and what the major bodies actually say. The goal is to help you understand the landscape and bring organized information to your pre-operative conversation, not to hand you a protocol to follow on your own.
The Short Version: Where the Guidance Stands in 2026
Here is the picture in plain terms:
This is a clinical-safety topic and a moving one. Nothing here is medical advice, and the decision for your procedure belongs to your surgeon and anesthesiologist.
Why GLP-1s Raise the Aspiration Question
To understand the guidance, it helps to understand the mechanism. GLP-1 receptor agonists work in part by slowing how quickly the stomach empties its contents into the small intestine. This delayed gastric emptying is part of how these medications produce the feeling of fullness that many users notice. You can read more about the individual compounds in our overviews of [semaglutide](/peptides/semaglutide) and [tirzepatide](/peptides/tirzepatide).
That same delayed emptying becomes relevant before anesthesia. Before most procedures, patients are told to fast so the stomach is empty, because general anesthesia and deep sedation suppress the airway reflexes that normally keep stomach contents out of the lungs. If gastric emptying is slowed by a GLP-1, food can still be present even after the usual fasting window has passed. If that retained material is regurgitated and enters the lungs, the result is pulmonary aspiration, which is the specific risk these warnings address.
This is why the topic is squarely a clinic and anesthesiology matter rather than something to manage solo. The interaction between a medication's pharmacology and the timing of a procedure is exactly the kind of judgment your care team is trained to make.
What the FDA, MHRA, and ASA Each Say
Three sets of guidance are most relevant, and they come from different angles. The table below summarizes them.
|---|---|---|
A few points are worth drawing out. First, the FDA action is a label change, which puts aspiration risk formally on the drug's safety record. Second, the MHRA alert is notable because it explicitly names the dual GIP/GLP-1 receptor agonists, the class that includes [tirzepatide](/peptides/tirzepatide), not only the single-agonist GLP-1s. Third, the ASA guidance is the one that translates the concern into an actionable pre-procedure approach, and it is the piece that changed most recently.
What Changed Between 2023 and 2024
The shift in the anesthesiology guidance is the part many people miss, and it matters for how you read older advice.
In 2023, the prevailing recommendation was simpler and more conservative: hold the GLP-1 medication before a procedure. That blanket approach was easy to communicate but blunt, because it meant interrupting a medication for everyone regardless of their individual situation.
In October 2024, the multi-society guidance, reaffirmed through 2025, replaced that blanket hold with a risk-stratified model. Instead of telling everyone to stop, the updated guidance says most patients can continue their GLP-1, paired with a dietary adjustment before the procedure: clear liquids only, and fasting from solids for 24 hours beforehand. The logic is that a longer liquids-only window gives the stomach more time to clear, addressing the delayed-emptying concern without an automatic medication interruption for every patient.
This is the single most important thing to understand if you find conflicting information online. Older 2023-era guidance that says to simply hold the drug has been superseded by the 2024 update. That is also precisely why you should not act on any version yourself: which framework applies to you, and how, is a clinical determination.
Who the Guidance Flags as Higher Risk
The 2024 guidance is risk-stratified, which means it points to factors that may push an individual toward more caution. The guidance describes risk stratification based on several considerations:
For patients who fall into higher-risk territory, the guidance supports using gastric point-of-care ultrasound to assess stomach contents before proceeding. In plain terms, that means a clinician can use ultrasound at the bedside to look at whether the stomach appears empty or still holds contents, and use that information to decide how to proceed. This is a tool your anesthesia team may use; it is not something you arrange or interpret yourself.
The takeaway is not that you should self-assess against this list. It is that your dose, your stage of treatment, and your current symptoms are all things your care team will want to know, which is exactly the kind of information good tracking makes easy to share.
Because the decision is risk-stratified and individual, the most useful thing you can do is arrive prepared. Your surgeon and anesthesiologist will generally want to know specifics about your GLP-1 use, and having them organized rather than recalled from memory makes the conversation more accurate.
Practical items to have ready for your provider:
A clean record of dose history and timing is the kind of thing that is easy to track over time and awkward to reconstruct on the spot. Tools like our [semaglutide dose log](/calculators/semaglutide) and [tirzepatide dose log](/calculators/tirzepatide) exist to help you keep that history organized so you can compare it over time and share it accurately. You can also browse the full [peptide library](/peptides) for plain-language overviews of how each compound works. For clinics, organizing this kind of pre-procedure intake is part of what a structured tracking workflow supports; see our [overview for clinics](/clinics).
To be clear about scope: this article does not tell you to stop, continue, time, or adjust your medication before a procedure. That instruction comes only from the clinicians managing your care, who can weigh your full situation against the current guidance.
What to Track: Biomarkers Worth Monitoring
Separate from any single procedure, people using GLP-1 medications, working alongside their providers, commonly keep an eye on metabolic and safety-relevant markers over time. The following are biomarkers researchers and clinicians frequently discuss in the context of GLP-1 therapy. None of this is a recommendation to test or treat; it is a list of what is commonly tracked so you can organize your own data and discuss it with your provider.
Tracking these consistently, rather than as scattered one-off results, is what makes the data genuinely useful in a clinical conversation. A single value is a snapshot; a trend line tells a story. You can browse the full [biomarker library](/biomarkers) for plain-language explanations of each test.
[Track your protocol, dose timing, and labs in one place with MyProtocolStack.](/auth/login?mode=signup)
Tracking these consistently, rather than as scattered one-off results, also fits the broader 2026 picture: as GLP-1 medications moved from niche to widespread use, the systems around them, from drug labeling to anesthesiology protocols, have been catching up. Keeping a clean, provider-ready record of your medication, dose history, and relevant labs means that whenever a clinical question comes up, whether a scheduled procedure, a dose change, or a routine review, you can bring real data rather than rough recollection.
Frequently Asked Questions
Do I need to stop my GLP-1 before surgery or anesthesia?
That decision belongs to your surgeon and anesthesiologist, not to a single fixed rule. The guidance changed: the October 2024 ASA multi-society guidance, reaffirmed through 2025, replaced the earlier 2023 advice to simply hold the medication with a risk-stratified approach. It says most patients can continue their GLP-1 but should take only clear liquids and fast from solids for 24 hours before a procedure. Because the right path depends on your dose, your stage of treatment, and your symptoms, you should follow the specific instructions of the clinicians managing your procedure.
Why are GLP-1 medications a concern before anesthesia?
GLP-1 medications slow gastric emptying, which means food can remain in the stomach even after the standard pre-procedure fasting window. General anesthesia and deep sedation suppress the airway reflexes that normally keep stomach contents out of the lungs, so retained food can raise the risk of pulmonary aspiration. This is why the FDA added a pulmonary-aspiration warning to GLP-1 drug labels and the UK MHRA issued a 2025 drug safety alert covering GLP-1 and dual GIP/GLP-1 receptor agonists.
What changed between the 2023 and 2024 guidance?
In 2023, the prevailing recommendation was to simply hold the GLP-1 medication before a procedure. In October 2024, the multi-society anesthesiology guidance, reaffirmed through 2025, walked that back and replaced the blanket hold with risk stratification. The updated approach says most patients can continue the medication but should switch to clear liquids and fast from solids for 24 hours before the procedure, with more caution for higher-risk patients.
Which patients are considered higher risk?
The 2024 guidance stratifies risk based on factors including being in active dose escalation, being at the maximum dose, and having active gastrointestinal symptoms such as nausea or vomiting. For higher-risk patients, the guidance supports using gastric point-of-care ultrasound to assess stomach contents before proceeding. Whether you fall into a higher-risk category, and what that means for your procedure, is a determination your anesthesia team makes.
What should I tell my provider before a procedure?
Bring the specifics: which GLP-1 or dual GIP/GLP-1 medication you take, your current dose and whether you are escalating or stable, the date and time of your most recent dose, and any recent gastrointestinal symptoms. MyProtocolStack does not provide medical advice and cannot tell you whether to stop or continue your medication. What you can do on your own is keep an organized record of your protocol and dose timing so your pre-operative conversation is grounded in accurate information.
Sources
1. UK Medicines and Healthcare products Regulatory Agency (MHRA), Drug Safety Update: "GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pulmonary aspiration during general anaesthesia or deep sedation." https://www.gov.uk/drug-safety-update/glp-1-and-dual-gip-slash-glp-1-receptor-agonists-potential-risk-of-pulmonary-aspiration-during-general-anaesthesia-or-deep-sedation
2. Journal of the Endocrine Society, review of GLP-1 receptor agonists and perioperative management. https://academic.oup.com/jes/article/9/9/bvaf088/8196040
3. The Medical Letter on Drugs and Therapeutics, on GLP-1 receptor agonists and aspiration risk before anesthesia. https://secure.medicalletter.org/TML-article-1718a
4. SN Comprehensive Clinical Medicine (Springer), on GLP-1 receptor agonists, gastric emptying, and perioperative aspiration risk. https://link.springer.com/article/10.1007/s42399-025-02079-9
*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*
MyProtocolStack is the between-visit tracking layer your EMR doesn’t cover. Patients self-onboard; clinicians get a visibility dashboard. No EMR integration required. Launch in 3–5 days.